<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="352f1797-e850-efb9-e063-6294a90a6442"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use MECLIZINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for MECLIZINE HYDROCHLORIDE TABLETS.
 <br/>
      <br/>
MECLIZINE HYDROCHLORIDE tablets, for oral use
 <br/>
Initial U.S. Approval: 1957
</title>
   <effectiveTime value="20250515"/>
   <setId root="2990e296-2d60-70c0-e063-6394a90abbe4"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
            <name>NuCare Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
                        <name>NuCare Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68071-3748" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="352f3fe2-1772-0178-e063-6294a90ace70"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250515"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68071-3748" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Meclizine Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Meclizine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="70710-1162" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5856J3G2A2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A POTATO</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="HDP7W44CIO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MECLIZINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3L5TQ84570" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MECLIZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="6" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68071-3748-6" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241218"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="4" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68071-3748-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250515"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213957" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201029"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>light yellow to yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">1162</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID1">
               <id root="2990d4f3-a55f-21cb-e063-6394a90a6c00"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID2">Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.</paragraph>
               </text>
               <effectiveTime value="20230828"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID4">Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults (
 
    <linkHtml href="#ID1">1</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID5">
               <id root="2990d4f3-a560-21cb-e063-6394a90a6c00"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230828"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Recommended dosage: 25 mg to 100 mg daily, in divided doses (
  
     <linkHtml href="#ID8">2.1</linkHtml>).
 
    </item>
                           <item>Tablets: Swallow whole (
  
     <linkHtml href="#ID8">2.2</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID6">
                     <id root="2990d4f3-a561-21cb-e063-6394a90a6c00"/>
                     <title>2.1 Recommended Dosage</title>
                     <text>
                        <paragraph ID="ID7">The recommended dosage is 25 mg to 100 mg daily administered orally, in divided doses, depending upon clinical response.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID8">
                     <id root="2990d4f3-a562-21cb-e063-6394a90a6c00"/>
                     <title>2.2 Administration Instructions</title>
                     <text>
                        <paragraph ID="ID9">Meclizine hydrochloride tablets must be swallowed whole.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID12">
               <id root="2990d4f3-a563-21cb-e063-6394a90a6c00"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>12.5 mg: Light blue to blue colored, spotted, oval shaped, biconvex uncoated tablet, debossed with '1161' on one side and plain on the other side</item>
                     <item>25 mg: Light yellow to yellow colored, spotted, oval shaped, biconvex uncoated tablets debossed with '1162' on one side and plain on the other side</item>
                  </list>
               </text>
               <effectiveTime value="20230828"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tablets: 12.5 mg, and 25 mg (
  
     <linkHtml href="#ID12">3</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID16">
               <id root="2990d4f3-a564-21cb-e063-6394a90a6c00"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID17">Meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients
 
  <content styleCode="italics">[see Adverse Reactions (
  
   <linkHtml href="#ID27">6</linkHtml>) and Description (
  
   <linkHtml href="#ID53">11</linkHtml>)].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230828"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID19">Meclizine hydrochloride tablets are contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients (
 
    <linkHtml href="#ID16">4</linkHtml>).

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID20">
               <id root="2990d4f3-a565-21cb-e063-6394a90a6c00"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20200626"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>  May cause drowsiness: Use caution when driving a car or operating dangerous machinery (
  
     <linkHtml href="#ID21">5.1</linkHtml>).
 
    </item>
                           <item>  Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland (
  
     <linkHtml href="#ID23">5.2</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID21">
                     <id root="2990d4f3-a566-21cb-e063-6394a90a6c00"/>
                     <title>5.1 Drowsiness</title>
                     <text>
                        <paragraph ID="ID22">Since drowsiness may occur with use of meclizine hydrochloride, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.</paragraph>
                        <paragraph>Patients should avoid alcoholic beverages while taking meclizine hydrochloride
 
  <sup> </sup>
                           <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID32">7.1</linkHtml>)].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID23">
                     <id root="2990d4f3-a567-21cb-e063-6394a90a6c00"/>
                     <title>5.2 Concurrent Medical Conditions</title>
                     <text>
                        <paragraph ID="ID24">Because of its potential anticholinergic action, meclizine hydrochloride
 
  <sup> </sup>should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID27">
               <id root="2990d4f3-a568-21cb-e063-6394a90a6c00"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="ID28">The following adverse reactions associated with the use of meclizine hydrochloride
 
  <sup> </sup>were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

 </paragraph>
                  <paragraph>Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported.</paragraph>
               </text>
               <effectiveTime value="20230828"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID30">Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported (
 
    <linkHtml href="#ID27">6</linkHtml>).

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="underline">www.fda.gov/medwatch</content>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID31">
               <id root="2990d4f3-a569-21cb-e063-6394a90a6c00"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20200626"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>  Coadministration of meclizine hydrochloride
  
     <sup/>with other CNS depressants, including alcohol, may result in increased CNS depression (
  
     <linkHtml href="#ID32">7.1</linkHtml>).
 
    </item>
                           <item>  CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride
  
     <sup/>and CYP2D6 inhibitors (
  
     <linkHtml href="#ID34">7.2</linkHtml>).
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID32">
                     <id root="2990d4f3-a56a-21cb-e063-6394a90a6c00"/>
                     <title>7.1 CNS Depressants</title>
                     <text>
                        <paragraph ID="ID33">There may be increased CNS depression when meclizine hydrochloride
 
  <sup> </sup>is administered concurrently with other CNS depressants, including alcohol
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID21">5.1</linkHtml>)]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID34">
                     <id root="2990d4f3-a56b-21cb-e063-6394a90a6c00"/>
                     <title>7.2 CYP2D6 Inhibitors</title>
                     <text>
                        <paragraph ID="ID35">Based on
 
  <content styleCode="italics">in-vitro</content>evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride
 
  <sup> </sup>and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID38">
               <id root="2990d4f3-a56c-21cb-e063-6394a90a6c00"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20200626"/>
               <component>
                  <section ID="ID39">
                     <id root="2990d4f3-a56d-21cb-e063-6394a90a6c00"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID40">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Data from epidemiological studies have not generally indicated a drug-associated risk of major birth defects with meclizine during pregnancy. However, in a published study, an increased incidence of fetal malformations was observed following oral administration of meclizine to pregnant rats during the period of organogenesis, at doses similar to those used clinically.</paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Epidemiological studies reporting on pregnancies exposed to meclizine have not identified an association between the use of meclizine during pregnancy and an increased risk of major birth defects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In a published study, oral administration of meclizine (25 mg/kg to 250 mg/kg) to pregnant rats during the period of organogenesis resulted in a high incidence of fetal malformations. These effects occurred at doses as low as 25 mg/kg, which is approximately 2 times the maximum recommended human dose (100 mg) on a body surface area (mg/m
 
  <sup>2</sup>) basis.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID41">
                     <id root="2990d4f3-a56e-21cb-e063-6394a90a6c00"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID42">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of meclizine in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for meclizine hydrochloride
 
  <sup> </sup>and any potential adverse effects on the breastfed infant from meclizine hydrochloride
 
  <sup> </sup>or from the underlying maternal condition.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID43">
                     <id root="2990d4f3-a56f-21cb-e063-6394a90a6c00"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID44">Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID45">
                     <id root="2990d4f3-a570-21cb-e063-6394a90a6c00"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID46">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID47">
                     <id root="2990d4f3-a571-21cb-e063-6394a90a6c00"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="ID48">The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine hydrochloride
 
  <sup> </sup>undergoes metabolism, hepatic impairment may result in increased systemic exposure of meclizine. Treatment with meclizine hydrochloride
 
  <sup> </sup>should be administered with caution in patients with hepatic impairment.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID49">
                     <id root="2990d4f3-a572-21cb-e063-6394a90a6c00"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID50">The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Because of a potential for drug/metabolite accumulation, meclizine hydrochloride
 
  <sup> </sup>should be administered with caution in patients with renal impairment and in the elderly, as renal function generally declines with age.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID51">
                     <id root="2990d4f3-a573-21cb-e063-6394a90a6c00"/>
                     <title>8.8 Genetic CYP2D6 Polymorphism</title>
                     <text>
                        <paragraph ID="ID52">The genetic polymorphism of CYP2D6 that results in poor-, intermediate-, extensive-, and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure. Therefore, when meclizine hydrochloride
 
  <sup> </sup>is administered to patients with CYP2D6 polymorphism, monitor for adverse reactions and clinical effect accordingly.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID53">
               <id root="2990d4f3-a574-21cb-e063-6394a90a6c00"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID54">Meclizine hydrochloride, a histamine (H1) receptor antagonist, is a white to slightly yellowish, crystalline powder. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID56">Chemically, meclizine hydrochloride, USP is 1-(p-chloro-α-phenylbenzyl)-4-(m-methylbenzyl) piperazine dihydrochloride monohydrate.</paragraph>
                  <paragraph>Inactive ingredients for the tablets are: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide and sodium starch glycolate. In addition, the 12.5 mg tablet contains FD&amp;C Blue # 1 Aluminum Lake; and the 25 mg tablet contains D&amp;C Yellow # 10 Aluminum Lake and FD&amp;C Yellow # 6 Aluminum Lake.</paragraph>
                  <paragraph>Each meclizine hydrochloride 12.5 mg tablet contains 12.5 mg of meclizine dihydrochloride equivalent to 10.53 mg of meclizine free base.</paragraph>
                  <paragraph>Each meclizine hydrochloride 25 mg tablet contains 25 mg of meclizine dihydrochloride equivalent to 21.07 mg of meclizine free base.</paragraph>
               </text>
               <effectiveTime value="20230828"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="70fc6598-0591-4201-83d4-01fa12f806e3-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID57">
               <id root="2990d4f3-a575-21cb-e063-6394a90a6c00"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20200626"/>
               <component>
                  <section ID="ID58">
                     <id root="2990d4f3-a576-21cb-e063-6394a90a6c00"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID59">The precise mechanism by which meclizine exerts its therapeutic effect is unknown but is presumed to involve antagonism of the histamine H1 receptor.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID60">
                     <id root="2990d4f3-a577-21cb-e063-6394a90a6c00"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID61">There are no relevant pharmacodynamic data regarding meclizine.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
               <component>
                  <section ID="ID62">
                     <id root="2990d4f3-a578-21cb-e063-6394a90a6c00"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID63">The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T
 
  <sub>max</sub>value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Drug distribution characteristics for meclizine in humans are unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Meclizine has a plasma elimination half-life of about 5 to 6 hours in humans.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>In an
 
  <content styleCode="italics">in vitro</content>metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

 </paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID64">
               <id root="2990d4f3-a579-21cb-e063-6394a90a6c00"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20200626"/>
               <component>
                  <section ID="ID65">
                     <id root="2990d4f3-a57a-21cb-e063-6394a90a6c00"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="ID66">
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>Animal studies to assess the carcinogenic potential of meclizine have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Genetic toxicology studies of meclizine have not been conducted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Animal studies to assess the effects of meclizine on fertility and early embryonic development have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID67">
               <id root="352f3e85-fede-fdaf-e063-6294a90a5b84"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>16.1 How Supplied</paragraph>
                  <paragraph/>
                  <paragraph>Meclizine Hydrochloride Tablets USP, 25 mg are light yellow to yellow colored, spotted, oval shaped, biconvex uncoated tablets debossed with '1162' on one side and plain on the other side and are supplied as follows:</paragraph>
                  <paragraph>NDC 68071-3748-4 in bottles of 4 tablets with child-resistance closure</paragraph>
                  <paragraph/>
                  <paragraph>16.2 Storage and Handling</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight, light-resistant container (USP).</paragraph>
               </text>
               <effectiveTime value="20250515"/>
               <component>
                  <section ID="ID68">
                     <id root="2990fe36-dfed-8fa4-e063-6294a90a264f"/>
                     <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Meclizine Hydrochloride Tablets USP, 25 mg are light yellow to yellow colored, spotted, oval shaped, biconvex uncoated tablets debossed with '1162' on one side and plain on the other side and are supplied as follows:</paragraph>
                        <paragraph>NDC 68071-3748-6 in bottles of 6 tablets with child-resistance closure</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241218"/>
                  </section>
               </component>
               <component>
                  <section ID="ID70">
                     <id root="2990d4f3-a57d-21cb-e063-6394a90a6c00"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Storage and Handling</title>
                     <text>
                        <paragraph ID="ID71">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>Dispense in a tight, light-resistant container (USP).</paragraph>
                     </text>
                     <effectiveTime value="20200626"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID72">
               <id root="2990d4f3-a57e-21cb-e063-6394a90a6c00"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID73">
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph>Advise patients that the tablets must be swallowed whole.
 
  <content styleCode="italics">[see Dosage and Administration (
  
   <linkHtml href="#ID6">2.1</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that meclizine hydrochloride
 
  <sup> </sup>may cause anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID21">5.1</linkHtml>), Adverse Reactions (
  
   <linkHtml href="#ID27">6</linkHtml>)].
 
  </content>
                  </paragraph>
                  <paragraph>Inform patients that meclizine hydrochloride
 
  <sup> </sup>may impair their ability to engage in potentially dangerous activities, such as operating machinery or vehicles.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Concomitant Drug Interactions</content>
                  </paragraph>
                  <paragraph>Advise patients regarding medications that should not be taken in combination with meclizine hydrochloride
 
  <sup> </sup>or that may necessitate increased monitoring
 
  <content styleCode="italics">[see Drug Interactions (
  
   <linkHtml href="#ID32">7.1</linkHtml>,
  
   <linkHtml href="#ID34">7.2</linkHtml>)].
 
  </content>Inform patients that alcohol may increase adverse reactions.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Concurrent Medical Conditions</content>
                  </paragraph>
                  <paragraph>Advise patients to notify their healthcare provider about all of their medical conditions, including if they are pregnant or plan to become pregnant or if they are breastfeeding
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#ID23">5.2</linkHtml>), Use in Specific Populations (
  
   <linkHtml href="#ID39">8.1</linkHtml>,
  
   <linkHtml href="#ID41">8.2</linkHtml>)]
 
  </content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Lifesciences Ltd.,</content>Ahmedabad, India

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Zydus Pharmaceuticals (USA) Inc.</content>
                  </paragraph>
                  <paragraph>Pennington, NJ 08534</paragraph>
                  <paragraph>Rev.: 08/23</paragraph>
               </text>
               <effectiveTime value="20230828"/>
            </section>
         </component>
         <component>
            <section ID="ID74">
               <id root="2990fa3f-ae2c-c4d5-e063-6394a90a308b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_2990e4ff-5bda-3008-e063-6294a90a9497"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241218"/>
               <component>
                  <observationMedia ID="img_2990e4ff-5bda-3008-e063-6294a90a9497">
                     <text>pdp</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="68071-3748-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>